Knight Therapeutics Inc. GUD.TO
TSX
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.92M | -2.43M | 9.60M | 6.35M | -2.75M |
| Total Depreciation and Amortization | 11.55M | 10.84M | 11.80M | 10.11M | 12.90M |
| Total Amortization of Deferred Charges | -- | -- | -- | 705.10K | -- |
| Total Other Non-Cash Items | 8.00M | 11.73M | 2.29M | -631.90K | 5.50M |
| Change in Net Operating Assets | 1.01M | 1.19M | 5.97M | 8.48M | -8.27M |
| Cash from Operations | 18.65M | 21.33M | 29.67M | 25.01M | 7.38M |
| Capital Expenditure | -228.70K | -448.70K | -2.42M | -362.20K | -297.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 0.00 | -- |
| Cash Acquisitions | -- | -6.10M | -- | 0.00 | -2.32M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.59M | 2.95M | 10.07M | -2.93M | 1.60M |
| Cash from Investing | 2.36M | -3.60M | 7.64M | -3.29M | -1.02M |
| Total Debt Issued | -- | -- | -- | 867.00K | -- |
| Total Debt Repaid | -2.63M | -38.39M | -12.54M | -29.85M | -5.01M |
| Issuance of Common Stock | 687.00K | 649.00K | 112.00K | 133.00K | 126.00K |
| Repurchase of Common Stock | -- | -1.04M | -8.24M | -3.00M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -306.00K | -1.93M | -649.00K | -2.95M | -1.03M |
| Cash from Financing | -1.61M | -29.41M | -15.53M | -24.96M | -4.29M |
| Foreign Exchange rate Adjustments | 45.00K | 1.20M | 1.26M | -657.80K | 880.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.44M | -10.48M | 23.04M | -3.89M | 2.95M |